Evidence is limited to animal or in-vitro work. No human pharmacokinetics. Any human dose in circulation is extrapolated, and extrapolation across species routinely fails.
No pharmacokinetic data found on allowed hosts.
A Khavinson-affiliated narrative review (PMC7583759) states Chonluten is given orally for bronchopulmonary pathology, but the accessible text gives no dose, frequency, or duration, and no primary controlled trial could be located.
Single Russian lineage. Allowed-host evidence: (1) an in-vitro THP-1 human monocyte/macrophage study (Avolio et al. 2022, PMC8999041) showing Chonluten inhibits LPS-induced TNF at 100 ng/mL; (2) a Khavinson-authored narrative review (PMC7583759) asserting oral clinical use without retrievable trial methodology, sample size, or dose. No independent non-Russian replication, no RCT. Sequence Glu-Asp-Gly and MW 319.27 Da confirmed on PubChem (CID 194641).
No human safety/toxicology data with dosing detail found on allowed hosts. No adverse-event reporting located for Chonluten specifically. Absence of reported harm is not evidence of safety.